Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill amends Medicare Part D to require that certain FDA‑labeled non‑opioid drugs for postoperative or acute pain (that do not act on opioid receptors, have no therapeutically equivalent product on the U.S. market, and meet a price threshold) be exempt from the Part D deductible, placed on the plan’s lowest cost‑sharing tier, and be covered without step therapy or prior authorization. The provisions apply to plan years beginning on or after January 1, 2026, and include conforming changes for low‑income subsidy cost‑sharing rules.
Liberals emphasize reduced barriers and addiction prevention
Narrow Medicare tweak with bipartisan appeal on opioid alternatives, but insurers and PBMs may oppose plan mandates.
The bill amends Medicare Part D to require that certain FDA‑labeled non‑opioid drugs for postoperative or acute pain (that do not act on opioid receptors, have no therapeutically equivalent product on the U.S. market, and meet a price threshold) be exempt from the Part D deductible, placed on the plan’s lowest cost‑sharing tier, and be covered without step therapy or prior authorization.
The provisions apply to plan years beginning on or after January 1, 2026, and include conforming changes for low‑income subsidy cost‑sharing rules.
Targeted, non-controversial public-health framing helps, but cost implications and insurer/industry pushback reduce prospects absent offsets or stakeholder deals.
How solid the drafting looks.
Liberals emphasize reduced barriers and addiction prevention
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize reduced barriers and addiction prevention
Likely supportive: this removes financial and administrative barriers to non‑opioid pain alternatives, aligning with efforts to reduce opioid prescriptions and addiction.
May want broader coverage for nonpharmacologic therapies and monitoring to ensure equitable access.
Cautiously favorable if budgetary impact is small and implementation is clear.
Sees public‑health value in reducing opioid use, but wants CBO scoring and guardrails against cost growth or unintended coverage expansion.
Likely skeptical or opposed: supports opioid‑reduction goals but objects to federal mandates on plan formularies and cost‑sharing.
Concerned about increased Medicare spending and federal intrusion into benefit design.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted, non-controversial public-health framing helps, but cost implications and insurer/industry pushback reduce prospects absent offsets or stakeholder deals.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize reduced barriers and addiction prevention
Targeted, non-controversial public-health framing helps, but cost implications and insurer/industry pushback reduce prospects absent offset…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Alternatives to PAIN Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.